Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.

de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard S, Hardiman G, Hussain M, Diehl JA, Drake JM, Kelly WK, Knudsen KE.

Clin Cancer Res. 2018 May 8. pii: clincanres.0410.2018. doi: 10.1158/1078-0432.CCR-18-0410. [Epub ahead of print]

PMID:
29739788
2.

Multidisciplinary Clinical Treatment of Head and Neck Cancer.

Mark JR, Kelly WK, Gomella LG.

JAMA Otolaryngol Head Neck Surg. 2018 Mar 15. doi: 10.1001/jamaoto.2017.3437. [Epub ahead of print] No abstract available.

PMID:
29543958
3.

Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, Fedele C, Liu Q, Tang HY, Kossenkov AV, Kelly WK, Wang K, Kean RB, Weinreb PH, Yu L, Dutta A, Fortina P, Ertel A, Stanczak M, Forsberg F, Gabrilovich DI, Speicher DW, Altieri DC, Languino LR.

Matrix Biol. 2018 Mar 9. pii: S0945-053X(18)30081-7. doi: 10.1016/j.matbio.2018.03.009. [Epub ahead of print]

PMID:
29530483
4.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
5.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

PMID:
29088323
6.

PARP Inhibitors in Prostate Cancer.

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.

Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2. Review.

PMID:
28540598
7.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

PMID:
28208174
8.

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.

Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, Cristofanilli M, Kelly WK.

Oncologist. 2016 Nov;21(11):1296-1297e. doi: 10.1634/theoncologist.2016-0297. Epub 2016 Oct 24.

9.

Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts.

Truong H, Hegarty SE, Gomella LG, Kelly WK, Trabulsi EJ, Lallas CD, Giri VN.

J Genet Couns. 2017 Jun;26(3):548-555. doi: 10.1007/s10897-016-0020-4. Epub 2017 Jan 19.

PMID:
28101821
10.

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.

Selvan SR, Dowling JP, Kelly WK, Lin J.

Curr Cancer Drug Targets. 2016;16(9):755-764. Review.

PMID:
26517538
11.

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.

Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB.

Urol Case Rep. 2016 Oct 1;9:51-54. eCollection 2016 Nov.

12.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

13.

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.

Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1193-200. doi: 10.1007/s00280-016-3033-7. Epub 2016 Apr 21.

PMID:
27103123
14.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ.

J Clin Oncol. 2016 May 10;34(14):1652-9. doi: 10.1200/JCO.2015.65.7270. Epub 2016 Mar 7.

15.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

16.

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Geethakumari PR, Cookson MS, Kelly WK; Prostate Cancer Clinical Trials Working Group 3.

Oncology (Williston Park). 2016 Feb;30(2):187-95, 199. Review.

17.

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.

Eur J Cancer. 2015 Sep;51(13):1714-24. doi: 10.1016/j.ejca.2015.05.019. Epub 2015 Jun 13.

18.

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Kelly WK, Marks P, Richon VM.

Clin Cancer Res. 2015 May 15;21(10):2198-200. doi: 10.1158/1078-0432.CCR-14-2556.

19.

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.

Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB.

Am J Clin Oncol. 2017 Aug;40(4):342-347. doi: 10.1097/COC.0000000000000181.

PMID:
25723740
20.

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, Kelly WK, Trabulsi EJ, Lallas CD, Gomella LG, Knudsen KE.

Clin Cancer Res. 2015 Feb 15;21(4):795-807. doi: 10.1158/1078-0432.CCR-14-1358.

Supplemental Content

Loading ...
Support Center